Stories from the dialysis comunity across the globe.
Dialysis and the good life - India Gazette
Expressing her worry at the 'distressing rise' in atrocities against Dalits across the country, Congress president Sonia Gandhi on Monday urged Prime Minister Narendra Modi to bring the SC/ST (Prevention of Atrocities) Bill for passage in the upcoming monsoon session of the Parliament.
"It is important for the ends of justice to ensure that a fair and impartial inquiry is conducted in these cases and the guilty are punished as per law. However, it is equally important to ensure that the institutional machinery charged with the welfare and protection of Dalits is strengthened and made accountable so that all Dalits are able to access justice as a matter of right," Sonia Gandhi wrote in a letter to Prime Minister Modi.
The Congress president termed it a disappointment that the NDA government had allowed the SC/ST (Prevention of Atrocities) Amendment Ordinance, 2014, to lapse by sending it to the standing committee.
"It is with this intention that the UPA-2 government brought in the SC/ST (Prevention of Atrocities) Amendment Ordinance, 2014 which among other things sought to strengthen the implementation of the SC and STs (Prevention of Atrocities Act, 1989). It is a matter of disappointment that NDA government allowed the ordinance to lapse by sending it to the standing committee," she said.
"I therefore urge you to bring the Bill for passage in the upcoming monsoon session," Sonia stated. (ANI)
Stock Update (NYSEMKT:CRMD): CorMedix Inc. Presents Neutrolin Post ... - Smarter Analyst
CorMedix Inc. (NYSEMKT:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. The Neutrolin Usage Monitoring Program is a post-approval surveillance program monitoring the routine use of Neutrolin, a novel catheter lock solution, in hemodialysis patients with tunneled central venous catheters (CVC). The program measures the number of catheter related blood stream infections (CRBSI), and the number of pre-mature CVC removals due to infection and/ or thrombosis. The secondary outcome measure was biofilm formation in CVCs. Other outcome measures included economic effects derived from using Neutrolin and effectiveness in the high risk groups (e.g. diabetic patients).
The poster, titled Neutrolin, A Catheter Lock Solution (CLS) with No Reported Human Resistance, Significantly Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study, was presented on May 30, 2015. In 120 patients, the results to-date include three infections and two thromboses in 21,151 hemodialysis catheter-days. The Neutrolin Usage Monitoring Program results can be calculated as 0.14 infections per 1,000 catheter days (versus benchmark of 3.5 per 1,000 catheter days), a 96% reduction in infection rate, and 0.09 thrombosis per 1,000 catheter days (versus benchmark 2-3 per 1,000 catheter days), a 96% reduction in the rate of thrombosis.
“This surveillance data continues to be very encouraging,” said Randy Milby, Chief Executive Officer, CorMedix. “We look forward to continuing to analyze the additional patient data in this effort to develop the optimum catheter lock solution, and address a critical medical need in the hemodialysis, oncology, and intensive care communities.”
Neutrolin is a novel formulation of taurolidine, citrate and heparin 1000 units/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis and biofilm to keep catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin has CE mark approval for use in the European Union and was recently approved to enter a Phase 3 program in the United States. The U.S. Food and Drug Administration (FDA) has designated Neutrolin as a Qualified Infectious Disease Product (QIDP), which provides an additional five years of market exclusivity in addition to the five years granted for a New Chemical Entity under Hatch-Waxman patent exclusivity. (Original Source)
Shares of Cormedix closed today at $7.10, up $1.01 or 16.58%. CRMD has a 1-year high of $10.40 and a 1-year low of $1.25. The stock’s 50-day moving average is $7.36 and its 200-day moving average is $4.85.
On the ratings front, Roth Capital analyst Scott Henry downgraded CRMD to Hold, with a price target of $7.50, in a report issued on May 6. The current price target represents a potential upside of 5.6% from where the stock is currently trading. According to TipRanks.com, Henry has a total average return of 27.0%, a 66.4% success rate, and is ranked #39 out of 3610 analysts.
Cormedix Inc is a development stage pharmaceutical and medical device company. It seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases, including the dialysis and non-dialysis areas.
CorMedix Presents Neutrolin® Post Marketing Surveillance Data at European ... - Military Technologies
BEDMINSTER, N.J., June 1, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. The Neutrolin Usage Monitoring Program is a post-approval surveillance program monitoring the routine use of Neutrolin, a novel catheter lock solution, in hemodialysis patients with tunneled central venous catheters (CVC). The program measures the number of catheter related blood stream infections (CRBSI), and the number of pre-mature CVC removals due to infection and/ or thrombosis. The secondary outcome measure was biofilm formation in CVCs. Other outcome measures included economic effects derived from using Neutrolin and effectiveness in the high risk groups (e.g. diabetic patients).
The poster, titled Neutrolin, A Catheter Lock Solution (CLS) with No Reported Human Resistance, Significantly Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study, was presented on May 30, 2015. In 120 patients, the results to-date include three infections and two thromboses in 21,151 hemodialysis catheter-days. The Neutrolin Usage Monitoring Program results can be calculated as 0.14 infections per 1,000 catheter days (versus benchmark of 3.5 per 1,000 catheter days), a 96% reduction in infection rate, and 0.09 thrombosis per 1,000 catheter days (versus benchmark 2-3 per 1,000 catheter days), a 96% reduction in the rate of thrombosis.
"This surveillance data continues to be very encouraging," said Randy Milby, Chief Executive Officer, CorMedix. "We look forward to continuing to analyze the additional patient data in this effort to develop the optimum catheter lock solution, and address a critical medical need in the hemodialysis, oncology, and intensive care communities."
Neutrolin is a novel formulation of taurolidine, citrate and heparin 1000 units/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis and biofilm to keep catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin has CE mark approval for use in the European Union and was recently approved to enter a Phase 3 program in the United States. The U.S. Food and Drug Administration (FDA) has designated Neutrolin as a Qualified Infectious Disease Product (QIDP), which provides an additional five years of market exclusivity in addition to the five years granted for a New Chemical Entity under Hatch-Waxman patent exclusivity.
About CorMedix Inc.
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information, visit www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, financing plans should be considered forward-looking. Risks applicable to CorMedix include the results of our studies and clinical trials, including the Neutrolin Usage Monitoring Program and are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CorMedix Presents Neutrolin® Post Marketing Surveillance Data at European ... - PR Newswire (press release)
BEDMINSTER, N.J., June 1, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. The Neutrolin Usage Monitoring Program is a post-approval surveillance program monitoring the routine use of Neutrolin, a novel catheter lock solution, in hemodialysis patients with tunneled central venous catheters (CVC). The program measures the number of catheter related blood stream infections (CRBSI), and the number of pre-mature CVC removals due to infection and/ or thrombosis. The secondary outcome measure was biofilm formation in CVCs. Other outcome measures included economic effects derived from using Neutrolin and effectiveness in the high risk groups (e.g. diabetic patients).
The poster, titled Neutrolin, A Catheter Lock Solution (CLS) with No Reported Human Resistance, Significantly Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study, was presented on May 30, 2015. In 120 patients, the results to-date include three infections and two thromboses in 21,151 hemodialysis catheter-days. The Neutrolin Usage Monitoring Program results can be calculated as 0.14 infections per 1,000 catheter days (versus benchmark of 3.5 per 1,000 catheter days), a 96% reduction in infection rate, and 0.09 thrombosis per 1,000 catheter days (versus benchmark 2-3 per 1,000 catheter days), a 96% reduction in the rate of thrombosis.
"This surveillance data continues to be very encouraging," said Randy Milby, Chief Executive Officer, CorMedix. "We look forward to continuing to analyze the additional patient data in this effort to develop the optimum catheter lock solution, and address a critical medical need in the hemodialysis, oncology, and intensive care communities."
Neutrolin is a novel formulation of taurolidine, citrate and heparin 1000 units/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis and biofilm to keep catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin has CE mark approval for use in the European Union and was recently approved to enter a Phase 3 program in the United States. The U.S. Food and Drug Administration (FDA) has designated Neutrolin as a Qualified Infectious Disease Product (QIDP), which provides an additional five years of market exclusivity in addition to the five years granted for a New Chemical Entity under Hatch-Waxman patent exclusivity.
About CorMedix Inc.
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information, visit www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, financing plans should be considered forward-looking. Risks applicable to CorMedix include the results of our studies and clinical trials, including the Neutrolin Usage Monitoring Program and are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Learn Why Steve Cohen's Point72 Asset Management Just Opened Huge ... - OctaFinance.com
Steve Cohen’s Point72 Asset Management New Position in NxStage Medical, Inc. (NASDAQ:NXTM)
Point72 Asset Management has filled a SC 13G form regarding Nxstage Medical, Inc 16.02 -0.19 -1.17%. Filing Link: 000089914015000460. Per Steve Cohen’s Point72 Asset Management’s filing, the filler now owns 5% of the Health Care-company, holding 3,163,744 shares.
NxStage Medical, Inc. (NASDAQ:NXTM) is a newly disclosed equity position for the hedge fund and the filing was required due to activity on May 29, 2015. This most probably shows Steve Cohen’s Point72 Asset Management’s confidence and optimism in the future of the company.
The hedge fund has been active in the Finance sector recently. In the fund’s latest 13F, it revealed several positions. This sector is 23% of Steve Cohen’s Point72 Asset Management’s US equities portfolio.
Nxstage Medical, Inc Hedge Funds Ownership
Latest SEC filings show 116 hedge funds and institutional investors own Nxstage Medical, Inc. The institutional ownership of the company in Q1 2015 is high, at 92.03% of the shares outstanding. They increased by 2370379 the total shares they hold. As of that quarter these institutional investors owned 58172942 shares. A total of 12 funds opened new positions in Nxstage Medical, Inc and 49 increased their holdings. There were 9 funds that closed their positions and 35 that reduced them.
7 investors have the firm in their Top 10. Some of these are: Cortina Asset Management Llc, Dafna Capital Management Llc, Oracle Investment Management Inc, Deerfield Management Co, First Light Asset Management Llc, Tamarack Capital Management Llc, Broadview Advisors Llc..
Altrinsic Global Advisors Llc is the most positive institutional investor on Nxstage Medical, Inc, with ownership of 666300 shares as of Q1 2015 for 0.25% of the fund’s portfolio. Cortina Asset Management Llc is another positive player owning 2155427 shares of the company or 1.61% of their stocks portfolio. CA Dafna Capital Management Llc have 4.87% of their stock portfolio invested in the stock for 366554. Further, Oracle Investment Management Inc disclosed it had purchased a stake worth 8.24% of the fund’s stock portfolio in the company. The NY Deerfield Management Company was also a notable investor in the firm, owning 5073050 shares. Nxstage Medical, Inc is 2.84% of the fund’s stock portfolio.
Company Profile
NxStage Medical, Inc. (NxStage)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
CorMedix Inc. (NYSEMKT:
